Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, Kwekkeboom DJ, Krenning EP, Baum RP, Paganelli G. Bodei L, et al. Among authors: nicolini s. Eur J Nucl Med Mol Imaging. 2016 May;43(5):839-851. doi: 10.1007/s00259-015-3250-z. Epub 2015 Nov 23. Eur J Nucl Med Mol Imaging. 2016. PMID: 26596723
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Ianniello A, Sansovini M, Severi S, Nicolini S, Grana CM, Massri K, Bongiovanni A, Antonuzzo L, Di Iorio V, Sarnelli A, Caroli P, Monti M, Scarpi E, Paganelli G. Ianniello A, et al. Among authors: nicolini s. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1040-6. doi: 10.1007/s00259-015-3262-8. Epub 2015 Nov 27. Eur J Nucl Med Mol Imaging. 2016. PMID: 26611427 Clinical Trial.
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Sansovini M, et al. Among authors: nicolini s. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499. doi: 10.1007/s00259-016-3533-z. Epub 2016 Oct 4. Eur J Nucl Med Mol Imaging. 2017. PMID: 27704193
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Sansovini M, et al. Among authors: nicolini s. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):352. doi: 10.1007/s00259-016-3558-3. Eur J Nucl Med Mol Imaging. 2017. PMID: 27807661 No abstract available.
Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers.
Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T. Liverani C, et al. Among authors: nicolini s. Dis Markers. 2018 Dec 2;2018:6878409. doi: 10.1155/2018/6878409. eCollection 2018. Dis Markers. 2018. PMID: 30627226 Free PMC article.
Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis.
Bongiovanni A, Liverani C, Recine F, Fausti V, Mercatali L, Vagheggini A, Spadazzi C, Miserocchi G, Cocchi C, Di Menna G, De Vita A, Severi S, Nicolini S, Ibrahim T. Bongiovanni A, et al. Among authors: nicolini s. Front Oncol. 2020 Apr 7;10:414. doi: 10.3389/fonc.2020.00414. eCollection 2020. Front Oncol. 2020. PMID: 32318336 Free PMC article.
43 results